SARI inhibits angiogenesis and tumour growth of human colon cancer through directly targeting ceruloplasmin
出版年份 2016 全文链接
标题
SARI inhibits angiogenesis and tumour growth of human colon cancer through directly targeting ceruloplasmin
作者
关键词
-
出版物
Nature Communications
Volume 7, Issue -, Pages 11996
出版商
Springer Nature
发表日期
2016-06-29
DOI
10.1038/ncomms11996
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- BATF2 Deficiency Promotes Progression in Human Colorectal Cancer via Activation of HGF/MET Signaling: A Potential Rationale for Combining MET Inhibitors with IFNs
- (2015) Z. Liu et al. CLINICAL CANCER RESEARCH
- Small GTPase RBJ Mediates Nuclear Entrapment of MEK1/MEK2 in Tumor Progression
- (2014) Taoyong Chen et al. CANCER CELL
- Progastrin a new pro-angiogenic factor in colorectal cancer
- (2014) S Najib et al. ONCOGENE
- Cancer statistics, 2013
- (2013) Rebecca Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Novel Mechanism of MDA-7/IL-24 Cancer-Specific Apoptosis through SARI Induction
- (2013) Rupesh Dash et al. CANCER RESEARCH
- Temporal and Pharmacological Characterization of Angiostatin Release and Generation by Human Platelets: Implications for Endothelial Cell Migration
- (2013) Aneta Radziwon-Balicka et al. PLoS One
- Ceruloplasmin alters intracellular iron regulated proteins and pathways: Ferritin, transferrin receptor, glutamate and hypoxia-inducible factor-1α
- (2012) J. Harned et al. EXPERIMENTAL EYE RESEARCH
- Adjuvant bevacizumab in colon cancer: where did we go wrong?
- (2012) Matthew T Seymour LANCET ONCOLOGY
- Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial
- (2012) Aimery de Gramont et al. LANCET ONCOLOGY
- Soluble Vascular Endothelial Growth Factor Decoy Receptor FP3 Exerts Potent Antiangiogenic Effects
- (2012) De-Chao Yu et al. MOLECULAR THERAPY
- The Function of SARI in Modulating Epithelial-Mesenchymal Transition and Lung Adenocarcinoma Metastasis
- (2012) Changli Wang et al. PLoS One
- Hallmarks of Cancer: The Next Generation
- (2011) Douglas Hanahan et al. CELL
- The transcription factor BATF controls the global regulators of class-switch recombination in both B cells and T cells
- (2011) Wataru Ise et al. NATURE IMMUNOLOGY
- Antiangiogenic therapy: impact on invasion, disease progression and metastasis
- (2011) John M. L. Ebos et al. Nature Reviews Clinical Oncology
- Plasmid-based STAT3-siRNA efficiently inhibits breast tumor growth and metastasis in mice
- (2011) L. DAI et al. NEOPLASMA
- Sunitinib Malate for the Treatment of Pancreatic Neuroendocrine Tumors
- (2011) Eric Raymond et al. NEW ENGLAND JOURNAL OF MEDICINE
- Double Antiangiogenic Protein, DAAP, Targeting VEGF-A and Angiopoietins in Tumor Angiogenesis, Metastasis, and Vascular Leakage
- (2010) Young Jun Koh et al. CANCER CELL
- Decreased expression of BATF2 is associated with a poor prognosis in hepatocellular carcinoma
- (2010) Haiqing Ma et al. INTERNATIONAL JOURNAL OF CANCER
- Collateral damage: toxic effects of targeted antiangiogenic therapies in ovarian cancer
- (2010) Rebecca L Stone et al. LANCET ONCOLOGY
- Inhibition of AP-1 by SARI negatively regulates transformation progression mediated by CCN1
- (2010) R Dash et al. ONCOGENE
- The Pfam protein families database
- (2009) Robert D. Finn et al. NUCLEIC ACIDS RESEARCH
- Cloning and characterization of SARI (suppressor of AP-1, regulated by IFN)
- (2008) Z.-z. Su et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Batf3 Deficiency Reveals a Critical Role for CD8 + Dendritic Cells in Cytotoxic T Cell Immunity
- (2008) K. Hildner et al. SCIENCE
- Regulation of metastasis in colorectal adenocarcinoma: A collision between development and tumor biology
- (2008) J. Joshua Smith et al. SURGERY
- Angiogenesis as a strategic target for ovarian cancer therapy
- (2008) Whitney A Spannuth et al. Nature clinical practice. Oncology
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search